Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Therapeutic efficacy of alpha-radioimmunotherapy with different activity levels of the Bi-213-labeled monoclonal antibody MX35 in an ovarian cancer model

Artikel i vetenskaplig tidskrift
Författare Anna Gustafsson-Lutz
Tom Bäck
Emma Aneheim
Ragnar Hultborn
Stig Palm
Lars Jacobsson
A. Morgenstern
F. Bruchertseifer
Per Albertsson
Sture Lindegren
Publicerad i EJNMMI Research
Volym 7
ISSN 2191-219X
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik
Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för onkologi
Språk English
Länkar dx.doi.org/10.1186/s13550-017-0283-...
Ämnesord Radioimmunotherapy, Dosimetry, High LET radiation, Monoclonal antibodies (mAb), CARCINOMA ASCITES-CELLS, NUDE-MICE, AT-211-MX35 F(AB')(2), LONG-TERM, PHARMACOKINETICS, MYELOTOXICITY, IRRADIATION, DOSIMETRY, BINDING, TH-229
Ämneskategorier Cancer och onkologi

Sammanfattning

Background: The aim of this study was to compare the therapeutic efficacy of two different activity levels of the Bi-213-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperitoneally with human ovarian cancer cells (OVCAR-3). Two weeks later, 40 mice were injected intraperitoneal (i.p.) with 1 ml of Bi-213-MX35, 3 MBq/mL (n = 20), or 9 MBq/mL (n = 20). An additional 20 mice received unlabeled MX35. Incidence of tumors and ascites was investigated 8 weeks after therapy. Body weight and white blood cell counts were monitored after treatment for possible signs of toxicity. Results: The tumor-free fraction of the animals treated with 3 MBq/mL of Bi-213-MX35 was 0.55, whereas that of animals treated with 9 MBq/mL of Bi-213-MX35 was 0.78. The control group treated with unlabeled MX35 had a tumor-free fraction of 0.15. No significant reduction in white blood cell counts or weight loss was observed. Conclusions: Tumor growth after i.p. treatment with Bi-213-MX35 was significantly reduced compared to treatment with unlabeled MX35. Treatment with 9 MBq/mL of Bi-213-MX35 resulted in higher tumor-free fraction compared with 3 MBq/mL of Bi-213-MX35, but this difference was not statistically significant. No signs of toxicity were observed in the treated animals.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?